OptimizeRx Corp. (Nasdaq: OPRX) announced it will hold a conference call on August 12, 2026, at 4:30 p.m. ET to discuss its second quarter 2026 financial results ended June 30, 2026. The call will include management remarks followed by a Q&A session, with details and webcast access provided for investors.

OptimizeRx Corp. announced the appointment of Sarah Bast as Chief Marketing Officer. Bast brings over 20 years of pharmaceutical marketing experience from roles at Publicis Health Media and major life sciences companies including Lilly, Bayer, Johnson & Johnson, and AstraZeneca. She will lead OptimizeRx's marketing strategy and go-to-market initiatives as the company expands its point-of-care technology solutions.

OptimizeRx announced the launch of its patent-pending Natural Language Audience Builder (NLAB), an AI-powered tool designed to be embedded in demand-side platforms and agency media planning platforms. The technology enables life sciences companies and marketers to build custom HCP audiences using natural-language prompts, combining real-world evidence with OptimizeRx's EHR network data. NLAB will be available for platform integration starting August 2026.

OptimizeRx Corp. announced four new partner agreements expanding its point-of-care network, increasing National Provider Identifier (NPI) reach by 37% through exclusive partnerships with e-prescribing platforms and health systems access partners.

OptimizeRx Corp. has received a purported notice of nominations from a stockholder, Whetstone Capital Advisors, LLC, regarding its intention to nominate two candidates for election to the OptimizeRx Board of Directors at the Company's 2025 Annual Meeting of Stockholders.

Smith Micro Software, Inc. reported a Q2 loss of $0.38 per share, missing the Zacks Consensus Estimate of a loss of $0.35. The company's revenue of $5.14 million also missed estimates. The stock has lost about 62.9% since the beginning of the year.

• 84% of Patients Arrive at Doctor Visits Underinformed• Underscores Growing Importance of HCP and DTC Alignment in Pharma Commercialization and Marketing Strategies• OPRX Closes First Combined HCP and DTC DAAP Marketing Program for Top 5 Pharma Client

OptimizeRx (NASDAQ:OPRX) has been analyzed by 5 analysts in the last three months, revealing a diverse range of perspectives from bullish to bearish. The table below offers a condensed view of their recent ratings, showcasing the changing sentiments over the past 30 days and comparing them to the preceding months. Bullish Somewhat Bullish Indifferent Somewhat Bearish Bearish Total Ratings 2 3 0 0 0 Last 30D 1 0 0 0 0 1M Ago 0 1 0 0 0 2M Ago 1 2 0 0 0 3M Ago 0 0 0 0 0 Analysts' evaluations of 12-month price targets offer additional insights, showcasing an average target of $14.6, with a high estimate of $17.00 and a low estimate of $13.00. This current average has increased by 12.31% from the previous average price target of $13.00. Breaking Down Analyst Ratings: A Detailed Examination The analysis of recent analyst actions sheds light on the perception of OptimizeRx by financial experts. The following summary presents key analysts, their recent evaluations, and adjustments to ratings and price targets. Analyst Analyst Firm Action Taken Rating Current Price Target Prior Price Target David Grossman Stifel Maintains Buy $13.00 $13.00 Constantine Davides JMP Securities Maintains Market Outperform $15.00 - Constantine Davides JMP Securities Announces Market Outperform $15.00 - David Grossman Stifel Maintains Buy $13.00 $13.00 Sean Dodge RBC Capital Maintains Outperform $17.00 - Key Insights: Action Taken: In response to dynamic market conditions and company performance, analysts update their recommendations. Whether they 'Maintain', 'Raise', ...Full story available on Benzinga.com

WALTHAM, Mass., May 14, 2024 (GLOBE NEWSWIRE) -- OptimizeRx Corp. (the “Company”) (Nasdaq: OPRX), the leading provider of healthcare technology solutions helping life sciences companies reach and engage healthcare professionals (HCPs) and patients, reported results for the three months ended March 31, 2024. Quarterly comparisons are to the same year-ago period.

The consensus price target hints at a 34.8% upside potential for OptimizeRx (OPRX). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.

WALTHAM, Mass., May 06, 2024 (GLOBE NEWSWIRE) -- OptimizeRx Corp. (the “Company”) (Nasdaq: OPRX), the leading provider of healthcare technology solutions helping life sciences companies reach and engage healthcare professional (HCPs) and patients, today announced that management will participate in the following upcoming investor conferences:

Open Text (OTEX) delivered earnings and revenue surprises of 0% and 1.36%, respectively, for the quarter ended March 2024. Do the numbers hold clues to what lies ahead for the stock?